Profile data is unavailable for this security.
About the company
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
- Revenue in USD (TTM)2.99bn
- Net income in USD-560.79m
- Incorporated2019
- Employees6.13k
- LocationBiontech SEAn der Goldgrube 12MAINZ 55131GermanyDEU
- Phone+49 49 613190840
- Fax+49 61 319084390
- Websitehttps://www.biontech.com/
Mergers & acquisitions
| Acquired company | 22UA:GER since announced | Transaction value |
|---|---|---|
| AexeRNA Therapeutics LLC | 19.01% | -- |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Therapeutics Corporation | 2.62bn | 1.07bn | 15.24bn | 1.17k | 15.75 | 2.67 | 13.49 | 5.82 | 21.75 | 21.75 | 53.16 | 128.25 | 0.3904 | 2.43 | 9.29 | 2,240,325.00 | 15.96 | 10.38 | 17.53 | 11.27 | 88.85 | 91.47 | 40.87 | 29.25 | 4.18 | -- | 0.0807 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Vaxcyte Inc | 0.00 | -497.19m | 15.48bn | 254.00 | -- | 6.49 | -- | -- | -4.62 | -4.62 | 0.00 | 17.96 | 0.00 | -- | -- | 0.00 | -27.70 | -34.22 | -28.85 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Summit Therapeutics Inc | 0.00 | -161.69m | 17.79bn | 105.00 | -- | 91.19 | -- | -- | -0.2299 | -0.2299 | 0.00 | 0.2693 | 0.00 | -- | -- | 0.00 | -55.83 | -77.32 | -75.71 | -86.35 | -- | -- | -- | -20,989.46 | -- | -51.01 | 0.3389 | -- | -100.00 | -- | -680.54 | -- | -4.84 | -- |
| ICON PLC | 8.33bn | 714.43m | 25.05bn | 41.10k | 35.15 | 2.61 | 19.13 | 3.01 | 8.60 | 8.60 | 100.31 | 115.74 | 0.489 | -- | 3.01 | 202,722.40 | 4.19 | 3.93 | 5.00 | 4.80 | 29.75 | 28.91 | 8.57 | 7.37 | -- | 3.86 | 0.264 | -- | 4.89 | 25.62 | 21.18 | 13.67 | 23.79 | -- |
| Moderna Inc | 5.05bn | -5.87bn | 26.85bn | 5.60k | -- | 2.29 | -- | 5.32 | -15.37 | -15.37 | 13.21 | 30.50 | 0.2689 | 3.12 | 25.57 | 901,785.70 | -31.24 | 20.95 | -36.58 | 29.51 | 65.60 | -- | -116.18 | 32.10 | 3.92 | -- | 0.0469 | 0.00 | -64.45 | 119.28 | -156.37 | -- | 46.22 | -- |
| BioNTech SE - ADR | 2.99bn | -560.79m | 27.49bn | 6.13k | -- | 1.30 | -- | 9.19 | -2.33 | -2.33 | 12.45 | 89.18 | 0.121 | 1.00 | 1.96 | 487,757.50 | -2.27 | 37.91 | -2.51 | 44.76 | 85.27 | 83.82 | -18.75 | 50.36 | 7.40 | -- | 0.0132 | 4.73 | -77.94 | 97.35 | -90.14 | -- | 60.06 | -- |
| Alnylam Pharmaceuticals, Inc. | 2.34bn | -72.94m | 35.07bn | 2.10k | -- | -- | -- | 14.96 | -0.6285 | -0.6285 | 18.39 | -0.024 | 0.6326 | 3.31 | 158.02 | 1,116,384.00 | -1.97 | -26.56 | -2.62 | -32.77 | 87.00 | 83.66 | -3.11 | -94.26 | 2.93 | 0.6753 | 1.00 | -- | 76.23 | 89.45 | 61.08 | -- | -13.29 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 30 Jun 2024 | 8.28m | 3.48% |
| PRIMECAP Management Co.as of 30 Jun 2024 | 4.79m | 2.02% |
| Flossbach von Storch AGas of 30 Jun 2024 | 4.38m | 1.84% |
| Harding Loevner LPas of 30 Jun 2024 | 2.93m | 1.23% |
| Temasek Holdings Pte Ltd. (Investment Management)as of 30 Jun 2024 | 1.81m | 0.76% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 1.57m | 0.66% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 1.02m | 0.43% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 955.98k | 0.40% |
| Capital Research & Management Co. (International Investors)as of 30 Jun 2024 | 743.08k | 0.31% |
| Quinn Opportunity Partners LLCas of 30 Jun 2024 | 683.29k | 0.29% |
